BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kostas A, Siakavellas SI, Kosmidis C, Takou A, Nikou J, Maropoulos G, Vlachogiannakos J, Papatheodoridis GV, Papaconstantinou I, Bamias G. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(41): 7387-7396 [PMID: 29151692 DOI: 10.3748/wjg.v23.i41.7387] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
Number Citing Articles
1 Acovic A, Markovic BS, Volarevic V, Kanjevac T, Vojvodic D, Velickovic M, Zdravkovic N, Ristic V. Lingua Plicata Associated with Increased Level of Proinflammatory Cytokines in Gingival Cervical Fluid: Possible New Sign in Ulcerative Colitis. Serbian Journal of Experimental and Clinical Research 2022;0. [DOI: 10.2478/sjecr-2021-0006] [Reference Citation Analysis]
2 Lee YJ, Park JH. Fecal Calprotectin Assay at an Early Stage of Treatment Can Be Used as a Surrogate Marker to Predict Clinical Remission and Mucosal Healing in Pediatric Crohn's Disease. Pediatr Gastroenterol Hepatol Nutr 2022;25:396-405. [PMID: 36148291 DOI: 10.5223/pghn.2022.25.5.396] [Reference Citation Analysis]
3 Makaro A, Dziki Ł, Fichna J, Włodarczyk M. On the Way to Improve Diagnostic Marker Panel for Acute Appendicitis in Adults: the Role of Calprotectin. Indian J Surg 2022;84:634-639. [DOI: 10.1007/s12262-021-03063-y] [Reference Citation Analysis]
4 Fiorino G, Danese S, Peyrin-Biroulet L, Sans M, Bonelli F, Calleri M, Zierold C, Pollastro R, Moretti F, Malesci A. LIAISON® Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study. United European Gastroenterol J 2022. [PMID: 35789124 DOI: 10.1002/ueg2.12268] [Reference Citation Analysis]
5 Cao WT, Huang R, Liu S, Fan YH, Xu MS, Xu Y, Ni H. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy. World J Gastroenterol 2022; 28(23): 2582-2596 [DOI: 10.3748/wjg.v28.i23.2582] [Reference Citation Analysis]
6 Grgić D, Golubić K, Brinar M, Krznarić Ž. Predictive value of faecal calprotectin in ulcerative colitis - single centre experience. Ann Med 2022;54:1570-7. [PMID: 35635011 DOI: 10.1080/07853890.2022.2082518] [Reference Citation Analysis]
7 Peng Z, Yi J, Liu X. A Low-FODMAP Diet Provides Benefits for Functional Gastrointestinal Symptoms but Not for Improving Stool Consistency and Mucosal Inflammation in IBD: A Systematic Review and Meta-Analysis. Nutrients 2022;14:2072. [DOI: 10.3390/nu14102072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Plevris N, Lees CW. Disease Monitoring in Inflammatory Bowel Disease: Evolving Principles and Possibilities. Gastroenterology 2022:S0016-5085(22)00078-6. [PMID: 35101422 DOI: 10.1053/j.gastro.2022.01.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Guo X, Huang C, Xu J, Xu H, Liu L, Zhao H, Wang J, Huang W, Peng W, Chen Y, Nie Y, Zhou Y, Zhou Y. Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease. Front Nutr 2022;8:818902. [DOI: 10.3389/fnut.2021.818902] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
10 Ge C, Lu Y, Shen H, Zhu L. Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis. Scand J Gastroenterol 2022;:1-12. [PMID: 34994661 DOI: 10.1080/00365521.2021.2022193] [Reference Citation Analysis]
11 Cao Y, Dai Y, Zhang L, Wang D, Hu W, Yu Q, Wang X, Yu P, Liu W, Ping Y, Sun T, Sang Y, Liu Z, Chen Y, Tao Z. Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin. J Inflamm Res 2021;14:6409-19. [PMID: 34880643 DOI: 10.2147/JIR.S342846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bertani L, Mumolo MG, Tapete G, Albano E, Baiano Svizzero G, Zanzi F, Ceccarelli L, Bellini M, Marchi S, Costa F. Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment. Eur J Gastroenterol Hepatol 2020;32:1091-8. [PMID: 32282400 DOI: 10.1097/MEG.0000000000001731] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 19.0] [Reference Citation Analysis]
13 Nardone OM, Shivaji UN, Ferruzza V, Ghosh S, Iacucci M. Soluble Blood Markers of Mucosal Healing in Inflammatory Bowel Disease: The Future of Noninvasive Monitoring. Inflamm Bowel Dis 2020;26:961-9. [PMID: 31587036 DOI: 10.1093/ibd/izz226] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
14 Fabiszewska S, Derda E, Szymanska E, Osiecki M, Kierkus J. Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases. J Clin Med 2021;10:2997. [PMID: 34279480 DOI: 10.3390/jcm10132997] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
15 Halligan S, Boone D, Archer L, Ahmad T, Bloom S, Rodriguez-Justo M, Taylor SA, Mallett S. Prognostic biomarkers to identify patients likely to develop severe Crohn's disease: a systematic review. Health Technol Assess 2021;25:1-66. [PMID: 34225839 DOI: 10.3310/hta25450] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Bromke MA, Neubauer K, Kempiński R, Krzystek-Korpacka M. Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis. J Clin Med 2021;10:2203. [PMID: 34069684 DOI: 10.3390/jcm10102203] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
17 Lucafò M, Curci D, Bramuzzo M, Alvisi P, Martelossi S, Silvestri T, Guastalla V, Labriola F, Stocco G, Decorti G. Serum Adalimumab Levels After Induction Are Associated With Long-Term Remission in Children With Inflammatory Bowel Disease. Front Pediatr 2021;9:646671. [PMID: 34017806 DOI: 10.3389/fped.2021.646671] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 State M, Negreanu L, Voiosu T, Voiosu A, Balanescu P, Mateescu RB. Surrogate markers of mucosal healing in inflammatory bowel disease: A systematic review. World J Gastroenterol 2021; 27(16): 1828-1840 [PMID: 33967560 DOI: 10.3748/wjg.v27.i16.1828] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
19 Leber A, Hontecillas R, Zoccoli-Rodriguez V, Colombel JF, Chauhan J, Ehrich M, Farinola N, Bassaganya-Riera J. The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial. Inflamm Bowel Dis 2020;26:643-52. [PMID: 31077582 DOI: 10.1093/ibd/izz094] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
20 Nuñez F P, Mahadevan U, Quera R, Bay C, Ibañez P. Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterología y Hepatología (English Edition) 2021;44:312-319. [DOI: 10.1016/j.gastre.2020.06.023] [Reference Citation Analysis]
21 Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021;160:1570-83. [PMID: 33359090 DOI: 10.1053/j.gastro.2020.12.031] [Cited by in Crossref: 349] [Cited by in F6Publishing: 382] [Article Influence: 349.0] [Reference Citation Analysis]
22 Lamers CR, de Roos NM, Bongers CCWG, Ten Haaf DSM, Hartman YAW, Witteman BJM, Hopman MTE. Repeated prolonged moderate-intensity walking exercise does not appear to have harmful effects on inflammatory markers in patients with inflammatory bowel disease. Scand J Gastroenterol. 2021;56:30-37. [PMID: 33211989 DOI: 10.1080/00365521.2020.1845791] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
23 Nuñez F P, Mahadevan U, Quera R, Bay C, Ibañez P. Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterol Hepatol 2021;44:312-9. [PMID: 33070988 DOI: 10.1016/j.gastrohep.2020.06.032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
24 Park SY. Age-Related Fecal Calprotectin Concentrations in Healthy Adults. Korean J Clin Lab Sci 2020;52:181-187. [DOI: 10.15324/kjcls.2020.52.3.181] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Taylor H, Serrano-Contreras JI, McDonald JAK, Epstein J, Fell JM, Seoane RC, Li JV, Marchesi JR, Hart AL. Multiomic features associated with mucosal healing and inflammation in paediatric Crohn's disease. Aliment Pharmacol Ther 2020;52:1491-502. [PMID: 32929796 DOI: 10.1111/apt.16086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
26 Langhorst J, Kairey L, Oberle A, Boone J, Dobos G, Juette H, Tannapfel A, Rueffer A. Assessing Histological Inflammatory Activity in Patients With Ulcerative Colitis: A Diagnostic Accuracy Study Testing Fecal Biomarkers Lactoferrin and Calprotectin. Crohn's & Colitis 360 2020;2. [DOI: 10.1093/crocol/otaa053] [Reference Citation Analysis]
27 Krzystek-Korpacka M, Kempiński R, Bromke M, Neubauer K. Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults. Diagnostics (Basel) 2020;10:E367. [PMID: 32498475 DOI: 10.3390/diagnostics10060367] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
28 Rowan CR, Cullen G, Mulcahy HE, Sheridan J, Moss AC, Ryan EJ, Doherty GA. DUBLIN [Degree of Ulcerative colitis Burden of Luminal Inflammation] Score, a Simple Method to Quantify Inflammatory Burden in Ulcerative Colitis. J Crohns Colitis. 2019;13:1365-1371. [PMID: 30911757 DOI: 10.1093/ecco-jcc/jjz067] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
29 Rottenstreich A, Mishael T, Granovsky SG, Koslowsky B, Schweistein H, Abitbol G, Goldin E, Shitrit AB. Clinical utility of fecal calprotectin in monitoring disease activity and predicting relapse in pregnant patients with inflammatory bowel diseases. Eur J Intern Med 2020;77:105-10. [PMID: 32197833 DOI: 10.1016/j.ejim.2020.03.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Ungaro R, Colombel JF, Lissoos T, Peyrin-Biroulet L. A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. Am J Gastroenterol. 2019;114:874-883. [PMID: 30908297 DOI: 10.14309/ajg.0000000000000183] [Cited by in Crossref: 107] [Cited by in F6Publishing: 113] [Article Influence: 53.5] [Reference Citation Analysis]
31 Takahashi N, Kitazawa C, Itani Y, Awaga Y, Hama A, Hayashi I, Takamatsu H. Exploratory clinical characterization of experimentally-induced ulcerative colitis nonhuman primates. Heliyon 2020;6:e03178. [PMID: 31938753 DOI: 10.1016/j.heliyon.2020.e03178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Capron M, Béghin L, Leclercq C, Labreuche J, Dendooven A, Standaert A, Delbeke M, Porcherie A, Nachury M, Boruchowicz A, Dupas JL, Fumery M, Paupard T, Catteau S, Deplanque D, Colombel JF, Desreumaux P. Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohn's Disease: A Pilot Study (ACROHNEM). J Clin Med 2019;9:E41. [PMID: 31878146 DOI: 10.3390/jcm9010041] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
33 Bertani L, Bodini G, Mumolo MG, de Bortoli N, Ceccarelli L, Frazzoni L, Tapete G, Albano E, Plaz Torres MC, Bellini M, Savarino E, Savarino V, Marchi S, Costa F. Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis. Dig Dis Sci 2020;65:2397-402. [DOI: 10.1007/s10620-019-05959-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
34 Tandon P, Leung K, Yusuf A, Huang VW. Noninvasive Methods For Assessing Inflammatory Bowel Disease Activity in Pregnancy: A Systematic Review. Journal of Clinical Gastroenterology 2019;53:574-81. [DOI: 10.1097/mcg.0000000000001244] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
35 Volarevic V, Zdravkovic N, Harrell CR, Arsenijevic N, Fellabaum C, Djonov V, Lukic ML, Simovic Markovic B. Galectin-3 Regulates Indoleamine-2,3-dioxygenase-Dependent Cross-Talk between Colon-Infiltrating Dendritic Cells and T Regulatory Cells and May Represent a Valuable Biomarker for Monitoring the Progression of Ulcerative Colitis. Cells 2019;8:E709. [PMID: 31336879 DOI: 10.3390/cells8070709] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
36 Ricciuto A, Griffiths AM. Clinical value of fecal calprotectin. Crit Rev Clin Lab Sci 2019;56:307-20. [PMID: 31088326 DOI: 10.1080/10408363.2019.1619159] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 12.3] [Reference Citation Analysis]
37 Kato J, Yoshida T, Hiraoka S. Prediction of treatment outcome and relapse in inflammatory bowel disease. Expert Rev Clin Immunol 2019;15:667-77. [PMID: 30873890 DOI: 10.1080/1744666X.2019.1593140] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
38 Foster AJ, Smyth M, Lakhani A, Jung B, Brant RF, Jacobson K. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients. World J Gastroenterol 2019; 25(10): 1266-1277 [PMID: 30886509 DOI: 10.3748/wjg.v25.i10.1266] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
39 Ma C, Battat R, Parker CE, Khanna R, Jairath V, Feagan BG. Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease? Expert Review of Gastroenterology & Hepatology 2019;13:319-30. [DOI: 10.1080/17474124.2019.1563481] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
40 Russo M, Miraglia C, Nouvenne A, Leandro G, Meschi T, De' Angelis GL, Di Mario F. Approach to gastroenterological diseases in primary care. Acta Biomed 2018;89:5-11. [PMID: 30561411 DOI: 10.23750/abm.v89i8-S.7973] [Reference Citation Analysis]
41 Ziv-Baran T, Hussey S, Sladek M, Amil Dias J, Martin de Carpi J, Miele E, Veres G, Lionetti P, Koletzko S, Nuti F, Paerregaard A, Kolho KL, Russell RK, Shaoul R, Weiner D, Sigall Boneh R, Escher J, Finnby L, Turner D, Levine A. Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new-onset paediatric Crohn's disease. Aliment Pharmacol Ther 2018;48:1242-50. [PMID: 30450578 DOI: 10.1111/apt.15016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
42 Acovic A, Simovic Markovic B, Gazdic M, Arsenijevic A, Jovicic N, Gajovic N, Jovanovic M, Zdravkovic N, Kanjevac T, Harrell CR, Fellabaum C, Dolicanin Z, Djonov V, Arsenijevic N, Lukic ML, Volarevic V. Indoleamine 2,3-dioxygenase-dependent expansion of T-regulatory cells maintains mucosal healing in ulcerative colitis. Therap Adv Gastroenterol. 2018;11:1756284818793558. [PMID: 30159037 DOI: 10.1177/1756284818793558] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
43 Uspenskaya YB, Belogubova SJ. DIAGNOSTIC POSSIBILITIES OF FECAL CALPROTECTIN APPLICATION IN PATIENTS WITH INFLAMMATORY DOWEL DISEASES DURING PREGNANCY (literature review and clinical observations). Koloproktologiâ 2018. [DOI: 10.33878/2073-7556-2018-0-2-95-101] [Reference Citation Analysis]
44 Ayling RM, Kok K. Fecal Calprotectin. Adv Clin Chem 2018;87:161-90. [PMID: 30342711 DOI: 10.1016/bs.acc.2018.07.005] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 17.5] [Reference Citation Analysis]